EVEROLIMUS TEVA^® TABLETS 10MG
(everolimus)
TEVA
HK Reg. No. HK-68853 (17 Sep, 2025)

Composition:¹

• Each tablet contains 10 mg everolimus

Indication:1

• Hormone receptor-positive advanced breast cancer

• Everolimus is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2/neu) negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor

• Neuroendocrine tumors of pancreatic origin

• Everolimus is indicated for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors of pancreatic origin in adults with progressive disease

• Neuroendocrine tumors of gastrointestinal or lung origin

• Everolimus is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumors of gastrointestinal or lung origin in adults with progressive disease

• Renal cell carcinoma

• Everolimus is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy

References

1. EMC. Everolimus 10 mg Tablets.4 April 2024. Available from: https://www.medicines.org.uk/emc/product/12240/smpc#gref. [Accessed 18 November 2025].